 Fulcrum Therapeutics Inc NASDAQ:FULC is trading higher again Wednesday after the stock saw positive analyst coverage following the companys better-than-expected financial results and announcement that its Phase 1 study of FTX-6058 for sickle cell disease showed proof of mechanism and proof of biology. We are very pleased with the interim results from this clinical trial of FTX-6058, which demonstrated compelling results across all primary, secondary, and exploratory endpoints included in this study, said Bryan Stuart, president and CEO of Fulcrum Therapeutics. 